Tag Archives: AstraZeneca

COVID vaccine weekly: AstraZeneca is safe and effective, but facing supply issues

Megan Clement, The Conversation The European Medicines Agency has said that the Oxford/AstraZeneca vaccine is safe and effective, and not associated with an increased overall risk of developing blood clots. The regulator conducted a review of the vaccine after a small number of people developed blood clots in Europe after receiving the vaccine. Thirteen countries suspended the use of the …

Read More »

Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout

Nigel William Crawford, Murdoch Children’s Research Institute; Hazel Clothier, Murdoch Children’s Research Institute, and Jim Buttery, The University of Melbourne Germany, France, Spain and all of Italy also paused their AstraZeneca rollouts, shortly after this article was published. Ireland and the Netherlands have temporarily paused their rollouts of the AstraZeneca COVID vaccine, due to concerns about blood clots. The move …

Read More »

Yes, export bans on vaccines are a problem, but why is the supply of vaccines so limited in the first place?

Cecilia Fabiano/AP Deborah Gleeson, La Trobe University News of the blockage of a shipment of 250,000 COVID-19 vaccines from Europe to Australia has caused concern and outrage. The immediate problem will probably be quickly solved through diplomatic channels. Even if it is not, onshore manufacturing of the AstraZeneca vaccine will soon make up for any shortfall in Australia’s vaccine supply. …

Read More »

COVID vaccine weekly: why AstraZeneca vaccine received WHO backing even as South Africa paused rollout

Rob Reddick, The Conversation As vaccine programmes gather pace worldwide, attention continues to focus on both viral mutations and the Oxford/AstraZeneca vaccine – sometimes simultaneously. South Africa has temporarily halted the vaccine’s rollout. This is because a preliminary study (yet to be released or reviewed by other scientists) suggests that the vaccine provides limited protection against mild to moderate cases …

Read More »

COVID-19 vaccines: how and when will lower-income countries get access?

Rory Horner, University of Manchester COVID-19 vaccination programmes are gathering pace in high-income countries, but for much of the world, the future looks bleaker. Although a number of middle-income countries have started rolling out vaccines, widespread vaccination could still be years away. The first two COVID-19 vaccines authorised in Europe and the United States – made by Pfizer/BioNTech and Moderna …

Read More »

Coronavirus: why combining the Oxford vaccine with Russia’s Sputnik V vaccine could make it more effective

Jim Barber/Shutterstock Jameel Inal, University of Hertfordshire When the efficacy of the Oxford/AstraZeneca vaccine was announced in late 2020, there was some confusion. The overall efficacy of the vaccine at stopping people developing symptomatic COVID-19, two weeks after the second dose, was 70%. But this wasn’t the whole picture. This figure was based on averaging the results from two groups. …

Read More »

Oxford scientists: how we developed our COVID-19 vaccine in record time

University of Oxford Tonia Thomas, University of Oxford and Rachel Colin-Jones, University of Oxford The pandemic is only a year old, but we already have multiple vaccines available to fight COVID-19 – including the vaccine developed by the team we’re part of at the University of Oxford. With our partner AstraZeneca, we have submitted both interim efficacy data and safety …

Read More »

How the leading coronavirus vaccines work

Eugene Lu/Shutterstock Sarah Pitt, University of Brighton There are now quite a few COVID-19 vaccines in the pipeline, but two seem to be making promising progress: the one designed by the US biotechnology company Moderna, and the one developed by the University of Oxford in collaboration with AstraZeneca. In both cases, the research teams have built on their previous experience …

Read More »